IO Biotech Inc (IOBT)

Form 8-K - Current report

Form 8-K - Current report

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

IO Biotech Provides Corporate Update

Raymond James engaged as financial advisorReduction in force implemented NEW YORK, Jan. 30, 2026 (GLOBE...

Form 8-K - Current report

IO Biotech Announces Exploration of Strategic Alternatives

NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical...

Form 8-K - Current report

IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications

Findings provide scientific insights into the contributions of IDO1 and PD-L1 vaccination to PD-1 blockade for...

IO Biotech Announces Participation in Upcoming December Investor Conferences

NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical...

Form 8-K - Current report

Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For

November 20th, 2025 -- InvestorsHub NewsWire -- via NetworkNewsWire Editorial Coverage: BioMedWire Editorial Coverage: As...

Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For

AUSTIN, Texas, Nov. 20, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: As late-stage biotech...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]